Pregabalin市场规模、份额、成长分析（按剂型、按应用、按药物类别、按分销管道、按最终用户、按地区）- 行业预测，2025 年至 2032 年

2023 年全球Pregabalin市场规模为 19 亿美元，预计将从 2024 年的 19.7 亿美元成长到 2032 年的 26.6 亿美元，预测期内（2025-2032 年）的复合年增长率为 3.8%。

由于癫痫、神经病变疼痛、纤维肌痛和焦虑等神经系统疾病的发生率不断上升，尤其是在 25-60 岁的成年人中，全球Pregabalin市场正在经历显着增长。根据世界卫生组织统计，全世界有超过 5,000 万人患有癫痫，其中 70% 的人如果得到适当治疗可以过上无癫痫发作的生活。成年人仍然是主要的消费群组，因为他们对这些慢性疾病高度敏感。此外，主要企业为改善低收入和服务欠缺地区的药物取得而做出的策略性努力正在帮助市场扩大。低收入国家约 75-90% 的癫痫患者得不到充分治疗，满足这项未满足的需求代表着一个巨大的成长机会。不断增长的目标人口和不断增加的全球疾病负担继续推动对Pregabalin治疗的市场需求。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析
• 案例研究
• 顾客购买行为分析

Pregabalin市场规模（依剂型划分）及复合年增长率（2025-2032）

• 市场概览
• 口服胶囊
• 口服溶液
• 口服锭剂
• 缓释製剂

Pregabalin市场规模（依应用）及复合年增长率（2025-2032）

• 市场概览
• 癫痫
• 神经病变疼痛
• 焦虑症
• 其他的

Pregabalin市场规模（按药物类别和复合年增长率） (2025-2032)

• 市场概览
• 纤维肌痛药物
• 抗惊厥药
• 其他的

Pregabalin市场规模（依通路划分）及复合年增长率（2025-2032）

• 市场概览
• 医院药房
• 零售药局
• 网路药局
• 其他的

Pregabalin市场规模（依最终用户划分）及复合年增长率（2025-2032）

• 市场概览
• 医院
• 专科诊所
• 居家护理
• 其他的

Pregabalin市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益同比对比（2022-2024 年）

主要企业简介

• Pfizer Inc.（US）
• GSK plc（UK）
• Novartis AG（Switzerland）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Sanofi（France）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• Zydus Cadila（India）
• Lupin（India）
• Amneal Pharmaceuticals LLC.（US）
• Cipla Inc.（US）
• Torrent Pharmaceuticals Ltd.（India）
• Aurobindo Pharma Limited（India）
• Glenmark Pharmaceuticals Limited（India）
• Medley Pharmaceuticals Ltd.（India）
• Genesisbiotec（India）
• Biomax Biotechnics（India）

结论和建议

Global Pregabalin Market size was valued at USD 1.9 billion in 2023 and is poised to grow from USD 1.97 billion in 2024 to USD 2.66 billion by 2032, growing at a CAGR of 3.8% during the forecast period (2025-2032).

The global pregabalin market is witnessing significant growth driven by the rising prevalence of neurological conditions such as epilepsy, neuropathic pain, fibromyalgia, and anxiety, especially among adults aged 25 to 60. According to WHO, over 50 million people suffer from epilepsy globally, with up to 70% potentially living seizure-free if properly treated. Adults remain the dominant consumer group due to their higher susceptibility to these chronic disorders. Additionally, strategic initiatives by key players to improve access in low-income and underserved regions are bolstering market expansion. With around 75-90% of epilepsy patients in low-income countries lacking adequate treatment, addressing this unmet need presents a major growth opportunity. The growing target population and increasing global disease burden continue to fuel market demand for pregabalin therapies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pregabalin market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pregabalin Market Segments Analysis

Global Pregabalin Market is segmented by Forms, Application, Drug Class, Distribution Channel, End User and region. Based on Forms, the market is segmented into Oral Capsule, Oral Solution, Oral Tablet and Extended Release. Based on Application, the market is segmented into Epilepsy, Neuropathic Pain, Anxiety Disorder and Others. Based on Drug Class, the market is segmented into Fibromyalgia Agents, Anticonvulsants and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others. Based on End User, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Pregabalin Market

The global pregabalin market is being significantly driven by the rising incidence of neuropathic pain and generalized anxiety disorders. Healthcare professionals in both developed and emerging markets are increasingly turning to pregabalin due to its dual therapeutic benefits for managing chronic pain as well as alleviating anxiety symptoms. In 2024, treatment guidelines in countries like Canada and Australia were updated to recognize pregabalin as a first-line option, further enhancing its adoption in both neurological and psychiatric treatments. This growing acceptance among medical practitioners is contributing to an upsurge in pregabalin's utilization worldwide, thereby expanding its market footprint.

Restraints in the Global Pregabalin Market

The global pregabalin market faces significant constraints primarily due to its classification as a controlled substance in many countries, which hampers its market growth. Regulatory restrictions, particularly concerning prescribing practices, stem from concerns about the drug's potential for abuse and dependence. This has resulted in a slower adoption rate within various healthcare settings, including general care units and outpatient services. For instance, in 2024, the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) reaffirmed pregabalin's status as a Schedule 3 medication, which imposes stricter prescription controls and additional record-keeping requirements, further deterring its use among outpatients and primary care providers.

Market Trends of the Global Pregabalin Market

The global pregabalin market is witnessing a robust upward trend, driven by the rising demand for effective neuropathic pain relief solutions. As chronic pain conditions, particularly among aging populations in North America and Europe, become more prevalent, pregabalin, notably branded as Lyrica, has emerged as a go-to therapeutic option for managing ailments such as diabetic neuropathy and post-herpetic neuralgia. To cater to this increasing demand, pharmaceutical companies are innovating by introducing specialized dosage and long-acting formulations. Notably, Pfizer has enhanced its Lyrica CR line with a new formulation specifically designed for geriatric patients, addressing crucial issues of tolerability and compliance, further propelling market growth.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Customer Buying Behavior Analysis

Global Pregabalin Market Size by Forms & CAGR (2025-2032)

• Market Overview
• Oral Capsule
• Oral Solution
• Oral Tablet
• Extended Release

Global Pregabalin Market Size by Application & CAGR (2025-2032)

• Market Overview
• Epilepsy
• Neuropathic Pain
• Anxiety Disorder
• Others

Global Pregabalin Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Fibromyalgia Agents
• Anticonvulsants
• Others

Global Pregabalin Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Global Pregabalin Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Specialty Clinics
• Homecare
• Others

Global Pregabalin Market Size & CAGR (2025-2032)

• North America (Forms, Application, Drug Class, Distribution Channel, End User)
  • US
  • Canada
• Europe (Forms, Application, Drug Class, Distribution Channel, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Forms, Application, Drug Class, Distribution Channel, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Forms, Application, Drug Class, Distribution Channel, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Forms, Application, Drug Class, Distribution Channel, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK plc (U.K.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Cadila (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amneal Pharmaceuticals LLC. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Torrent Pharmaceuticals Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Glenmark Pharmaceuticals Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medley Pharmaceuticals Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genesisbiotec (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biomax Biotechnics (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations